| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article
- Language: English
- [Arch Gynecol Obstet] 2024 Jun; Vol. 309 (6), pp. 2789-2798. <i>Date of Electronic Publication: </i>2024 Feb 28.
- MeSH Terms: Breast Neoplasms* / blood ; Breast Neoplasms* / mortality ; Glycoproteins* / blood ; Humans ; Female ; Middle Aged ; Aged ; Adult ; Biomarkers, Tumor / blood ; Prognosis ; Kaplan-Meier Estimate ; Aged, 80 and over ; Proportional Hazards Models
- References: Takahashi N, Takahashi Y, Putnam FW (1985) Periodicity of leucine and tandem repetition of a 24-amino acid segment in the primary structure of leucine-rich alpha 2-glycoprotein of human serum. Proc Natl Acad Sci 82:1906–1910. (PMID: 3856868397442) ; Camilli C, Hoeh AE, De Rossi G, Moss SE, Greenwood J (2022) LRG1: an emerging player in disease pathogenesis. J Biomed Sci 29:1–29. ; Ng A, Xavier RJ (2011) Leucine-rich repeat (LRR) proteins: integrators of pattern recognition and signaling in immunity. Autophagy 7:1082–1084. (PMID: 216066813901792) ; Shirai R, Hirano F, Ohkura N, Ikeda K, Inoue S (2009) Up-regulation of the expression of leucine-rich α2-glycoprotein in hepatocytes by the mediators of acute-phase response. Biochem Biophys Res Commun 382:776–779. (PMID: 193240107092932) ; O’Donnell LC, Druhan LJ, Avalos BR (2002) Molecular characterization and expression analysis of leucine-rich alpha2-glycoprotein, a novel marker of granulocytic differentiation. J Leukoc Biol 72:478–485. (PMID: 12223515) ; Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA-K, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist P-H, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Pontén F (2015) Tissue-based map of the human proteome. Science (80- ) 347(6220):1260419. ; Wang X, Abraham S, McKenzie JAG, Jeffs N, Swire M, Tripathi VB, Luhmann UFO, Lange CAK, Zhai Z, Arthur HM, Bainbridge JWB, Moss SE, Greenwood J (2013) LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling. Nature 499:306–311. (PMID: 23868260) ; Mundo L, Tosi GM, Lazzi S, Pertile G, Parolini B, Neri G, Posarelli M, De Benedetto E, Bacci T, Silvestri E, Siciliano MC, Barbera S, Orlandini M, Greenwood J, Moss SE, Galvagni F (2021) LRG1 expression is elevated in the eyes of patients with neovascular age-related macular degeneration. Int J Mol Sci 22:1–12. ; Chen C, Chen X, Huang H, Han C, Qu Y, Jin H, Niu T, Zhang Y, Liu K, Xu X (2019) Elevated plasma and vitreous levels of leucine-rich-α2-glycoprotein are associated with diabetic retinopathy progression. Acta Ophthalmol 97:260–264. (PMID: 29168314) ; De Rossi G, Da Vitoria Lobo ME, Greenwood J, Moss SE (2022) LRG1 as a novel therapeutic target in eye disease. Eye 36:328–340. (PMID: 349871998807626) ; Hong Q, Zhang L, Fu J, Verghese DA, Chauhan K, Nadkarni GN, Li Z, Ju W, Kretzler M, Cai G-Y, Chen X-M, D’Agati VD, Coca SG, Schlondorff D, He JC, Lee K (2019) LRG1 promotes diabetic kidney disease progression by enhancing TGF-β-induced angiogenesis. J Am Soc Nephrol 30:546–562. (PMID: 308582256442349) ; Liu TT, Luo R, Yang Y, Cheng YC, Chang D, Dai W, Li YQ, Ge SW, Xu G (2021) LRG1 mitigates renal interstitial fibrosis through alleviating capillary rarefaction and inhibiting inflammatory and pro-fibrotic cytokines. Am J Nephrol 52:228–238. (PMID: 33823527) ; Serada S, Fujimoto M, Ogata A, Terabe F, Hirano T, Iijima H, Shinzaki S, Nishikawa T, Ohkawara T, Iwahori K, Ohguro N, Kishimoto T, Naka T (2010) iTRAQ-based proteomic identification of leucine-rich α-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis 69:770–774. (PMID: 19854709) ; Serada S, Fujimoto M, Terabe F, Iijima H, Shinzaki S, Matsuzaki S, Ohkawara T, Nezu R, Nakajima S, Kobayashi T, Plevy SE, Takehara T, Naka T (2012) Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis 18:2169–2179. (PMID: 22374925) ; Zou Y, Xu Y, Chen X, Wu Y, Fu L, Lv Y (2022) Research progress on leucine-rich alpha-2 glycoprotein 1: a review. Front Pharmacol 12:1–11. ; Liu C, Teo MHY, Pek SLT, Wu X, Leong ML, Tay HM, Hou HW, Ruedl C, Moss SE, Greenwood J, Tavintharan S, Hong W, Wang X (2020) A multifunctional role of leucine-rich α-2-glycoprotein 1 in cutaneous wound healing under normal and diabetic conditions. Diabetes 69:2467–2480. (PMID: 328876747576570) ; Nakajima H, Nakajima K, Serada S, Fujimoto M, Naka T, Sano S (2021) The involvement of leucine-rich α-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model. Mod Rheumatol 31:1120–1128. (PMID: 33535851) ; He L, Feng A, Guo H, Huang H, Deng Q, Zhao E, Yang M (2022) LRG1 mediated by ATF3 promotes growth and angiogenesis of gastric cancer by regulating the SRC/STAT3/VEGFA pathway. Gastric Cancer 25:527–541. (PMID: 35094168) ; Zhong B, Cheng B, Huang X, Xiao Q, Niu Z, Feng CY, Yu Q, Wang W, Wu XJ (2022) Colorectal cancer-associated fibroblasts promote metastasis by up-regulating LRG1 through stromal IL-6/STAT3 signaling. Cell Death Dis 13:1–15. ; Xie ZB, Zhang YF, Jin C, Mao YS, Fu DL (2019) LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling. J Exp Clin Cancer Res 38:1–12. ; Singhal M, Gengenbacher N, Pari AAA, Kamiyama M, Hai L, Kuhn BJ, Kallenberg DM, Kulkarni SR, Camilli C, Preuß SF, Leuchs B, Mogler C, Espinet E, Besemfelder E, Heide D, Heikenwalder M, Sprick MR, Trumpp A, Krijgsveld J, Schlesner M, Hu J, Moss SE, Greenwood J, Augustin HG (2021) Temporal multi-omics identifies LRG1 as a vascular niche instructor of metastasis. Sci Transl Med 13:1–14. ; Zhang J, Zhu L, Fang J, Ge Z, Li X (2016) LRG1 modulates epithelial–mesenchymal transition and angiogenesis in colorectal cancer via HIF-1α activation. J Exp Clin Cancer Res 35:1–11. ; Fan M, Li C, He P, Fu Y, Li M, Zhao X (2019) Knockdown of long noncoding RNA-taurine-upregulated gene 1 inhibits tumor angiogenesis in ovarian cancer by regulating leucine-rich α-2-glycoprotein-1. Anticancer Drugs 30:562–570. (PMID: 30896502) ; Zhang Q, Huang R, Tang Q, Yu Y, Huang Q, Chen Y, Wang G, Wang X (2018) Leucine-rich alpha-2-glycoprotein-1 is up-regulated in colorectal cancer and is a tumor promoter. Onco Targets Ther 11:2745–2752. (PMID: 297851235955028) ; Guldvik IJ, Zuber V, Braadland PR, Grytli HH, Ramberg H, Lilleby W, Thiede B, Zucknick M, Saatcioglu F, Gislefoss R, Kvåle R, George A, Grönberg H, Wiklund F, Neal DE, Gnanapragasam VJ, Taskén KA, Mills IG (2020) Identification and validation of leucine-rich α-2-glycoprotein 1 as a noninvasive biomarker for improved precision in prostate cancer risk stratification. Eur Urol Open Sci 21:51–60. (PMID: 343374688317831) ; Kwan YP, Teo MHY, Lim JCW, Tan MS, Rosellinny G, Wahli W, Wang X (2021) LRG1 promotes metastatic dissemination of melanoma through regulating EGFR/STAT 3 signalling. Cancers (Basel) 13:1–16. ; Shinozaki E, Tanabe K, Akiyoshi T, Tsuchida T, Miyazaki Y, Kojima N, Igarashi M, Ueno M, Suenaga M, Mizunuma N, Yamaguchi K, Nakayama K, Iijima S, Yamaguchi T (2018) Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker. BMC Cancer 18:1–9. ; Andersen JD, Boylan KLM, Jemmerson R, Geller MA, Misemer B, Harrington KM, Weivoda S, Witthuhn BA, Argenta P, Vogel RI, Skubitz APN (2010) Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. J Ovarian Res 3(1):1–14. ; Ladd JJ, Busald T, Johnson MM, Zhang Q, Pitteri SJ, Wang H, Brenner DE, Lampe PD, Kucherlapati R, Feng Z, Prentice RL, Hanash SM (2012) Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women. Cancer Prev Res 5:655–664. ; Zhou Y, Zhang X, Zhang J, Fang J, Ge Z, Li X (2017) LRG1 promotes proliferation and inhibits apoptosis in colorectal cancer cells via RUNX1 activation. PLoS ONE 12:1–14. ; Okano T, Kondo T, Kakisaka T, Fujii K, Yamada M, Kato H, Nishimura T, Gemma A, Kudoh S, Hirohashi S (2006) Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 6:3938–3948. (PMID: 16767791) ; Kawakami T, Hoshida Y, Kanai F, Tanaka Y, Tateishi K, Ikenoue T, Obi S, Sato S, Teratani T, Shiina S, Kawabe T, Suzuki T, Hatano N, Taniguchi H, Omata M (2005) Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics 5:4287–4295. (PMID: 16254924) ; Furukawa K, Kawamoto K, Eguchi H, Tanemura M, Tanida T, Tomimaru Y, Akita H, Hama N, Wada H, Kobayashi S, Nonaka Y, Takamatsu S, Shinzaki S, Kumada T, Satomura S, Ito T, Serada S, Naka T, Mori M, Doki Y, Miyoshi E, Nagano H (2015) Clinicopathological significance of leucine-rich α2-glycoprotein-1 in sera of patients with pancreatic cancer. Pancreas 44:93–98. (PMID: 25058884) ; Zhang YS, Han L, Yang C, Liu YJ, Zhang XM (2021) Prognostic value of LRG1 in breast cancer: a retrospective study. Oncol Res Treat 44(1):36–41. (PMID: 33242858) ; Jemmerson R, Staskus K, Higgins LA, Conklin K, Kelekar A (2021) Intracellular leucine-rich alpha-2-glycoprotein-1 competes with Apaf-1 for binding cytochrome c in protecting MCF-7 breast cancer cells from apoptosis. Apoptosis 26:71–82. (PMID: 333864927904597) ; Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8:329–340. (PMID: 18404148) ; Hartkopf AD, Wallwiener M, Hahn M, Fehm TN, Brucker SY, Taran F-A (2016) Simultaneous detection of disseminated and circulating tumor cells in primary breast cancer patients. Cancer Res Treat 48:115–124. (PMID: 25687853) ; Friberg S, Nyström A (2015) Cancer metastases: early dissemination and late recurrences. Cancer Growth Metastasis 8:43–49. (PMID: 266403894664198) ; Hartkopf AD, Brucker SY, Taran F-A, Harbeck N, von Au A, Naume B, Pierga J-Y, Hoffmann O, Beckmann MW, Rydén L, Fehm T, Aft R, Solà M, Walter V, Rack B, Schuetz F, Borgen E, Ta M-H, Bittner A-K, Fasching PA, Fernö M, Krawczyk N, Weilbaecher K, Margelí M, Hahn M, Jueckstock J, Domschke C, Bidard F-C, Kasimir-Bauer S, Schoenfisch B, Kurt AG, Wallwiener M, Gebauer G, Klein CA, Wallwiener D, Janni W, Pantel K (2021) Disseminated tumour cells from the bone marrow of early breast cancer patients: results from an international pooled analysis. Eur J Cancer 154:128–137. (PMID: 34265505) ; Rachner TD, Göbel A, Hoffmann O, Erdmann K, Kasimir-Bauer S, Breining D, Kimmig R, Hofbauer LC, Bittner A-K (2020) High serum levels of periostin are associated with a poor survival in breast cancer. Breast Cancer Res Treat 180:515–524. (PMID: 32040688) ; Rachner TD, Kasimir-Bauer S, Gobel A, Erdmann K, Hoffmann O, Browne A, Wimberger P, Rauner M, Hofbauer LC, Kimmig R, Bittner A-K (2019) Prognostic value of RANKL/OPG serum levels and disseminated tumor cells in nonmetastatic breast cancer. Clin Cancer Res 25(4):1369–1378. (PMID: 30425091) ; McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235. (PMID: 16932852) ; Kommission Mamma | Leitlinien & Empfehlungen | Leitlinien & Stellungnahmen | AGO – Die Arbeitsgemeinschaft Gynäkologische Onkologie [Internet]. [cited 2023 May 4]. Available from: https://www.ago-online.de/leitlinien-empfehlungen/leitlinien-empfehlungen/kommission-mamma. ; Kasimir-Bauer S, Reiter K, Aktas B, Bittner AK, Weber S, Keller T, Kimmig R, Hoffmann O (2016) Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: influence of bisphosphonate intake? Sci Rep 6:1–10. ; Xiao S, Zhu H (2018) Leucine-rich alpha-2-glycoprotein1 gene interferes with regulation of apoptosis in leukemia KASUMI-1 cells. Med Sci Monit 24:8348–8356. (PMID: 304554126256841) ; O’Connor MN, Kallenberg DM, Camilli C, Pilotti C, Dritsoula A, Jackstadt R, Bowers CE, Watson HA, Alatsatianos M, Ohme J, Dowsett L, George J, Blackburn JWD, Wang X, Singhal M, Augustin HG, Ager A, Sansom OJ, Moss SE, Greenwood J (2021) LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency. Med 2:1231-1252.e10. (PMID: 35590198) ; Javaid F, Pilotti C, Camilli C, Kallenberg D, Bahou C, Blackburn J, Baker R, Greenwood J, Moss SE, Chudasama V (2021) Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target. RSC Chem Biol 2:1206–1220. ; Wang Y, Xu J, Zhang X, Wang C, Huang Y, Dai K, Zhang X (2017) TNF-α-induced LRG1 promotes angiogenesis and mesenchymal stem cell migration in the subchondral bone during osteoarthritis. Cell Death Dis 8:e2715. (PMID: 283583725386532) ; Druhan LJ, Lance A, Li S, Price AE, Emerson JT, Baxter SA, Gerber JM, Avalos BR (2017) Leucine rich α-2 glycoprotein: a novel neutrophil granule protein and modulator of myelopoiesis. Rishi A, editor. PLoS One 12:e0170261. ; Alberro A, Iribarren-Lopez A, Sáenz-Cuesta M, Matheu A, Vergara I, Otaegui D (2021) Inflammaging markers characteristic of advanced age show similar levels with frailty and dependency. Sci Rep 11:1–10. ; Pek SLT, Tavintharan S, Wang X, Lim SC, Woon K, Yeoh LY, Ng X, Liu J, Sum CF (2015) Elevation of a novel angiogenic factor, leucine-rich-α2-glycoprotein (LRG1), is associated with arterial stiffness, endothelial dysfunction, and peripheral arterial disease in patients with type 2 diabetes. J Clin Endocrinol Metab 100:1586–1593. (PMID: 25636050) ; Pitteri SJ, Hanash SM, Aragaki A, Amon LM, Chen L, Busald Buson T, Paczesny S, Katayama H, Wang H, Johnson MM, Zhang Q, McIntosh M, Wang P, Kooperberg C, Rossouw JE, Jackson RD, Manson JE, Hsia J, Liu S, Martin L, Prentice RL (2009) Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med 1:121. (PMID: 200343932808737) ; Ramirez-Ardila DE, Ruigrok-Ritstier K, Helmijr JC, Look MP, van Laere S, Dirix L, Berns EMJJ, Jansen MPHM (2016) LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome. Mol Oncol 10:1363–1373. (PMID: 274918615423197)
- Grant Information: GO 3055/4-1 Deutsche Forschungsgemeinschaft; HO 1875/27-1 Deutsche Forschungsgemeinschaft; RA 2151/5-1 Deutsche Forschungsgemeinschaft; RA 2151/7-1 Deutsche Forschungsgemeinschaft
- Contributed Indexing: Keywords: LRG-1; Early breast cancer; Prognostic marker; Serum marker; Minimal residual disease; Disseminated tumor cells
- Substance Nomenclature: 0 (LRG1 protein, human) ; 0 (Glycoproteins) ; 0 (Biomarkers, Tumor)
- Entry Date(s): Date Created: 20240227 Date Completed: 20240603 Latest Revision: 20240624
- Update Code: 20240625
- PubMed Central ID: PMC11147863
|
